09887.HK
Nanjing Leads Biolabs Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 64.00
−5.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 195.5M | 197.2M | — | 9.8M | — |
| Cost of Revenue | — | — | — | 3.5M | 17.8M |
| Gross Profit | 195.5M | 197.2M | — | 6.3M | (17.8M) |
| Operating Expenses | |||||
| R&D Expense | 193.3M | 321.6M | 27.1M | 254.0M | 172.7M |
| SG&A Expense | 57.1M | 92.0M | 12.8M | 41.9M | 23.1M |
| General & Admin Expense | 56.8M | 91.6M | 12.7M | 41.3M | — |
| Selling & Marketing Expense | 230.8K | 446.1K | 62.1K | 567.8K | — |
| Other Expenses | 8.00 | 8.00 | — | — | — |
| Total Operating Expenses | 250.3M | 413.6M | 39.8M | 295.9M | 195.8M |
| Cost and Expenses | 250.3M | 413.6M | 39.8M | 299.4M | 213.5M |
| Operating Income (EBIT) | (54.8M) | (216.4M) | (39.8M) | (289.6M) | (213.5M) |
| Non-Operating | |||||
| Interest Income | 5.4M | 28.8M | 8.3M | 6.6M | 2.4M |
| Interest Expense | 3.6M | 7.0M | 5.8M | 1.4M | 303.3K |
| Net Interest Income | 24.5M | 21.8M | 2.5M | 5.2M | 2.1M |
| Other Non-Op Income/Expense | (2.7M) | (1.5M) | (4.1M) | (109.0M) | (73.2M) |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (57.5M) | (217.9M) | (43.9M) | (398.6M) | (286.8M) |
| Income Tax Expense | 17.1M | 17.3M | — | — | — |
| Bottom Line | |||||
| Net Income | (74.7M) | (235.2M) | (43.9M) | (398.6M) | (286.8M) |
| Earnings from Cont. Ops | (74.7M) | (235.2M) | (43.9M) | (398.6M) | (286.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (74.7M) | (235.2M) | (43.9M) | (398.6M) | (286.8M) |
| Per Share | |||||
| Basic EPS | (HK$0.42) | (HK$1.35) | (HK$0.29) | (HK$2.76) | (HK$1.51) |
| Diluted EPS | (HK$0.42) | (HK$1.35) | (HK$0.29) | (HK$2.76) | (HK$1.51) |
| Revenue Per Share | HK$1.02 | HK$1.13 | HK$0.00 | HK$0.07 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 191.8M | 174.1M | 150.0M | 144.9M | 188.6M |
| Diluted Shares Outstanding | 191.8M | 174.1M | 150.0M | 144.9M | 188.6M |
| Profitability Metrics | |||||
| EBITDA | (43.7M) | (199.0M) | (36.9M) | (267.9M) | (195.8M) |
| D&A | 11.2M | 17.4M | 2.9M | 21.7M | 17.8M |
| EBIT | (54.8M) | (216.4M) | (39.8M) | (289.6M) | (213.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025